Search | Clinical Trials Finder

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Clarithromycin, Azithromycin, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 11
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more

Conditions: Pulmonary Sarcoidosis, Lung Function
Interventions: levaquin; ethambutol; rifampin and azithromycin.; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy
Interventions: MK-4646, Rifabutin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Bacterial Infections, Mycoses, HIV Infections
Interventions: Clarithromycin, Rifabutin, Sulfamethoxazole-Trimethoprim, Dapsone, Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 2
States / cities: San Francisco, California • Seattle, Washington

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Rifabutin, Ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Clarithromycin, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more

Conditions: Staphylococcus Aureus, HIV Infections
Interventions: rifabutin plus trimethoprim sulfamethoxazole, placebo plus trimethoprim-sulfamethoxazole; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Saint Davids, Pennsylvania

Conditions: Tuberculosis
Interventions: Imatinib, Isoniazid, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Opioid Dependency, HIV Infections
Interventions: Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mycobacterium Avium Complex Lung Disease
Interventions: clarithromycin, rifabutin; Drug
Lead sponsor: The University of Texas Health Science Center at Tyler; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2017
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Azithromycin, Rifabutin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • San Diego, California + 7 more

Conditions: HIV Infections, Tuberculosis
Interventions: Rifabutin; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more

Conditions: Dyspepsia, Helicobacter Pylori Infection
Interventions: RHB-105, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Anaheim, California • Chino, California • Jupiter, Florida + 8 more

Conditions: Drug Drug Interaction
Interventions: Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg], Rifabutin 300mg; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Tuberculosis
Interventions: Nelfinavir mesylate, Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Lamivudine, Rifabutin, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions: Vesatolimod, Cobicistat, Voriconazole, Rifabutin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Long Beach, California • Miami, Florida • West Palm Beach, Florida + 1 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Ethambutol hydrochloride, Clarithromycin, Clofazimine, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Rifabutin; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1349572, Rifampin, Rifabutin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 22 more

Conditions: Crohn's Disease
Interventions: RHB-104, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 43
States / cities: Tucson, Arizona • Anaheim, California • La Mirada, California + 37 more

Conditions: HIV, Tuberculosis
Interventions: lopinavir/ritonavir, rifabutin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Waukegan, Illinois

Search by objective public record fields.

The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients

Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis

A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS

A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites

Drug-drug Interaction (DDI) Rifabutin

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects